Promega's patent battle with Roche over the taq enzyme used in the polymerase chain reaction (PCR) process will be decided in the autumn. The trial ended last week with Madison, Wisconsin-based Promega confident that its argument had persuaded the federal district judge in a San Francisco court that Roche's US patent was obtained by fraud.
The judge will now consider written submissions from both sides and a ruling is expected in late summer or early...